159873-06-0

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
1-(2,3-Epoxypropyl)-4-tert-butoxycarbonylpiperazine is utilized as a building block for the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides due to its unique structural properties.
Used in Peptide and Amino Acid Derivative Formation:
In the field of peptide chemistry, Boc-EP is employed as a component in the formation of peptides and amino acid derivatives, enhancing the functional diversity and potential applications of these biologically active molecules.

InChI:InChI=1/C12H22N2O3/c1-12(2,3)17-11(15)14-6-4-13(5-7-14)8-10-9-16-10/h10H,4-9H2,1-3H3

Upstream product

• 106-89-8 epichlorohydrin 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 115314-14-2 (R)-glycidyl nosylate 
• 3132-64-7 1,2-Epoxy-3-bromopropane 

Downstream Products

• 335165-68-9 Bax channel blocker 
• 335166-36-4 (+/-)-3,6-Dibromo-9-(2-fluoro-3-piperazin-1-yl-propyl)-carbazole 

Relevant academic research and scientific papers

3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models

Cyclin-dependent kinases are therapeutic targets frequently deregulated in various cancers. By convenient alkylation of the 5-sulfanyl group, we synthesized 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with various substitutions at position 5 with potent antiproliferative activity in non-Hodgkin lymphoma cell lines. The most potent derivative 4.35 also displayed activities across more than 60 cancer cell lines. The kinase profiling confirmed high selectivity of 4.35 toward cyclin-dependent kinases (CDKs) 2, 5, and 9, and the cocrystal with CDK2/cyclin A2 revealed its binding in the active site. Cultured lymphoma cell lines treated with 4.35 showed dephosphorylation of CDK substrates, cleavage of PARP-1, downregulation of XIAP and MCL-1, and activation of caspases, which collectively confirmed ongoing apoptosis. Moreover, 4.35 demonstrated significant activity in various cell line xenograft and patient-derived xenograft mouse models in vivo both as a monotherapy and as a combination therapy with the BCL2-targeting venetoclax. These findings support further studies of combinatorial treatment based on CDK inhibitors.

SMALL MOLECULE BAX INHIBITORS AND USES THEREOF

Compounds, compositions and method of using these compounds are disclosed for treating a disease or disorder in which it is desirable to inhibit BAX, such as a cardiovascular disease or disorder.

3,6-Dibromocarbazole piperazine derivatives of 2-propanol as first inhibitors of cytochrome C release via bax channel modulation

There is compelling evidence that Bax channel activity stimulates cytochrome c release leading ultimate]y to cell death, which is a key event in ischemic injuries and neurodegenerative diseases. Here 3,6-dibromocarbazole piperazine derivatives of 2-propan

9-(Piperazinylalkyl)carbazoles as Bax-modulators

The present invention is related to piperazine derivatives of carbazole notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such piperazine derivatives of carbazole. Said piperazine derivatives of car

Piperazine and homopiperazine derivatives, pharmaceutical compositions containing them and process for preparing same

This invention relates to novel compounds of the general formula (I) and the pharmaceutically acceptable acid addition salts thereof. In the general formula (I) STR1 wherein Lip, A1, A2, Het and n are defined as in the specification. The compounds of the general formula (I) inhibit the lipid peroxidation and therefore, they are useful for the treatment or prevention of diseases and conditions wherein the inhibition of lipid peroxidation is desirable.